Paradigm Biopharmaceuticals is developing an osteoarthritis treatment that looks simpler to make, easier to deliver, and less likely to run into surprise safety and regulator issues than a more complex rival approach. With key trial updates ahead, the company could narrow what the author sees as a big gap between its current market value and what similar programs are being priced at.Read more